Factors affecting relative dose intensity in patients with Hodgkin lymphoma (HL) receiving doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) without granulocyte-colony stimulating factor (G-CSF) support

被引：0
|
作者：
Kirui, L. C. [1 ]
Cwynarski, K. [1 ]
McNamara, C. [1 ]
机构：
[1] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
135
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [1] Increased dose intensity (DI) of doxorubicin and vinblastine during ABVD therapy of Hodgkin's lymphoma with the use of granulocyte colony stimulating factor (GCSF).
    Raybon, K
    Schroeder, M
    Allerton, J
    BLOOD, 1995, 86 (10) : 3270 - 3270
  • [2] Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study
    Minuk, Leonard A.
    Monkman, Katherine
    Chin-Yee, Ian H.
    Lazo-Langner, Alejandro
    Bhagirath, Vinai
    Chin-Yee, Benjamin H.
    Mangel, Joy E.
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 57 - 63
  • [3] Short duration filgrastim (G-CSF) therapy (24 days) is adequate to maintain dose intensity in Hodgkin's lymphoma patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Kammer, Lynne S.
    Bavisi, Seema
    Lawton, Jessica
    Uhlig, William
    Carro, George
    Grinblatt, David L.
    BLOOD, 2006, 108 (11) : 255B - 255B
  • [4] Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients
    Miller, K
    LEUKEMIA RESEARCH, 1998, 22 : S13 - S16
  • [5] Granulocyte-Colony Stimulating Factor (G-CSF) in Secondary Prophylaxis for Advanced-Stage Hodgkin Lymphoma Treated with ABVD Chemotherapy: A Cost-Effectiveness Analysis
    Cheung, Matthew C.
    Prica, Anca
    Graczyk, Joanna
    Buckstein, Rena
    Chan, Kelvin K. W.
    BLOOD, 2014, 124 (21)
  • [6] Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor
    Gastaldi, R
    Martino, P
    Gentile, G
    Picardi, V
    De Propris, MS
    Pirillo, MF
    De Vellis, A
    Mandelli, F
    ANNALS OF ONCOLOGY, 2002, 13 (07) : 1158 - 1160
  • [7] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
    Vitolo, Umberto
    Angrili, Francesco
    DeCosta, Lucy
    Wetten, Sally
    Federico, Massimo
    MEDICAL ONCOLOGY, 2016, 33 (12)
  • [8] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin’s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
    Umberto Vitolo
    Francesco Angrili
    Lucy DeCosta
    Sally Wetten
    Massimo Federico
    Medical Oncology, 2016, 33
  • [9] BLEOMYCIN-INDUCED PULMONARY FIBROSIS (BPF) IN HODGKIN LYMPHOMA (HL) PATIENTS: IS GRANOLOCYTE-COLONY STIMULATING FACTOR (G-CSF) A RISK FACTOR?
    Bentzen, H. H.
    Mortensen, L. S.
    Pulczynski, E. J.
    Gilstrom, D. B.
    Jorgensen, J. M.
    ANNALS OF ONCOLOGY, 2011, 22 : 181 - 181
  • [10] Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)
    Girling, DJ
    Thatcher, N
    Clark, PI
    Stephens, RJ
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) : 1263 - 1263
12345